Tenderwize
Retour à la recherche

Open house pharmaceutical rebate agreements Ribociclib, ATC L01EF02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2028 · 644 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ribociclib, ATC L01EF02

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The open-house model does not guarantee any purchase volume; actual revenue depends on usage by AOK Bayern members.

The agreement automatically terminates if a public rebate contract for the same active substance is concluded, which co...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Supply of the pharmaceutical product Ribociclib (ATC L01EF02) to AOK Bayern under non-exclusive rebate agreements.
  • Contracts are identical and non-negotiable, following an open-house model.
Afficher le résumé complet

Open house non-exclusive pharmaceutical rebate agreement for Ribociclib (ATC L01EF02) by AOK Bayern. The contracting authority intends to conclude identical, non-negotiable rebate agreements with any interested pharmaceutical company that meets the eligibility criteria. The agreement is not subject to procurement law according to the buyer. Contracts can be concluded from 01.08.2026 to 31.07.2028, with ongoing entry possible until 03.06.2028. No estimated value is provided.

Risques

The open-house model does not guarantee any purchase volume; actual revenue depends on usage by AOK Bayern members.

The agreement automatically terminates if a public rebate contract for the same active substance is concluded, which co...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Submission of a signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and a signed declaration of reliability.
  • Documents must be submitted either in paper form (two original copies, hand-signed) or electronically with a qualified electronic signature via the communication area of the...

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house pharmaceutical rebate agreements Ribociclib, ATC L01EF02

Non-exclusive rebate agreements for the active substance Ribociclib, ATC code L01EF02, for the supply of pharmaceutical products to AOK Bayern. Contracts are identical and non-negotiable. Performance in Bavaria, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 03, 2028

Détails de la procédure

Date de publication
14 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
408105-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30